Vertex's kidney disease drug meets main goal in late-stage trial

March 9 (Reuters) - Vertex Pharmaceuticals said on Monday that its experimental kidney disease drug met the main goal of a late-stage trial. Shares of the company were up about 10% in extended trading. Vertex was testing the drug, povetacicept, in patients with IgA nephropathy, a serious autoimmune disease that can lead to kidney failure or death in a large proportion of patients within 20 years